https://www.zacks.com/stock/news/2266520/cf-cf-reports-q1-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2266520
May 01, 2024 - The headline numbers for CF (CF) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zc:-5541492751772165674
0
https://seekingalpha.com/news/4093770-eqt-to-pursue-500m-cfday-mountain-valley-pipeline-expansion?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Apr 24, 2024 - EQT plans to expand the capacity of the Mountain Valley Pipeline after acquiring Equitrans Midstream, in response to increased gas demand in the southeast U.S.
0
sa:-293277499875652018
0
https://www.zacks.com/stock/news/2255409/pick-these-4-low-p-cf-stocks-to-boost-your-portfolio?cid=CS-ZC-FT-analyst_blog|rw-2255409
Apr 15, 2024 - Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. PAGS, ATGE, KBH & GM boast a low P/CF ratio.
zc:7447666147922720525
0
https://www.zacks.com/stock/news/2253953/nutrien-ntr-gains-on-strong-demand-amid-pricing-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253953
Apr 11, 2024 - While Nutrien (NTR) faces pricing headwinds, it benefits from solid demand for fertilizers, backed by the strength in global agriculture markets.
zc:7630981351759028721
0
https://www.zacks.com/stock/news/2248414/design-a-balanced-portfolio-with-these-4-low-p-cf-stocks?cid=CS-ZC-FT-analyst_blog|rw-2248414
Apr 01, 2024 - Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. ATGE, GM, UNM & KBH boast low P/CF ratios.
zc:4405781837303413982
0
https://www.zacks.com/stock/news/2227473/company-news-for-feb-16-2024?cid=CS-ZC-FT-corporate_summary-2227473
Feb 16, 2024 - Companies in The News Are:HBI,WEN,ET,CF
zc:7092769057628201414
0
https://www.zacks.com/stock/news/2226492/cf-cf-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2226492
Feb 14, 2024 - While the top- and bottom-line numbers for CF (CF) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zc:1332261986309812116
0
https://www.zacks.com/stock/news/2224005/insights-into-cf-cf-q4-wall-street-projections-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2224005
Feb 09, 2024 - Evaluate the expected performance of CF (CF) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
zc:-4904919434498953248
0
https://seekingalpha.com/news/4062897-vertex-to-seek-fda-ema-approval-for-vanza-triple-therapy-for-cf?source=feed_sector_healthcare
Feb 05, 2024 - Vertex Pharmaceuticals (VRTX) reported positive Phase 3 study results for its vanza triple therapy in the treatment of cystic fibrosis and plans to seek US and
0
sa:-3436292191452051880
0
https://seekingalpha.com/news/4057428-4d-molecular-gets-fda-rare-pediatric-disease-status-for-cf-drug?source=feed_sector_healthcare
Jan 23, 2024 - 4D Molecular Therapeutics (FDMT) has received FDA rare pediatric disease designation for its cystic fibrosis drug candidate 4D-710. Read more here.
0
sa:2890690695634487798
0